Texas Instruments Stock Falls After Q2 Earnings: Here’s Why

Texas Instruments Incorporated (NASDAQ: TXN) shares are trading lower in Tuesday's after-hours session on the heels of the company's second-quarter report.

Texas Instruments Incorporated (NASDAQ:TXN) shares are trading lower in Tuesday’s after-hours session on the heels of the company’s second-quarter report. Here’s a rundown of the results and a look at what’s driving the action.

What Happened: The company reported quarterly earnings of $1.87 per share, a 23.67% decrease over earnings of $2.45 per share from the same period last year. It reported quarterly sales of $4.53 billion, which beat the analyst consensus estimate of $4.37 billion, a 13.07% decrease over sales of $5.21 billion in the same period last year.

Texas Instruments expects third-quarter revenue between $4.36 billion and $4.74 billion, versus the consensus estimate of $4.60 billion. Furthermore, the company estimates earnings per share between $1.68 and $1.92, versus the consensus estimate of $1.91.

Haviv Ilan, TI’s president and CEO, among other things, acknowledged cash flow metrics, saying, “Our cash flow from operations of $7.4 billion for the trailing 12 months again underscored the strength of our business model, the quality of our product portfolio and the benefit of 300-mm production. Free cash flow for the same period was $3.2 billion and 17% of revenue.”

Related Link: What’s Going On With SoFi Stock Today?

TXN Price Action: TXN shares were down 2.43% after hours at $181.55 at the time of publication, according to Benzinga Pro.

Image by Dan Williams from Pixabay

Total
0
Shares
Related Posts
Read More

Aprea Unveils Initial Clinical Data On ATRi, ATRN-119, And Pre-Clinical Data On WEE1i, ATRN-1051, At AACR-NCI-EORTC International Conference Supporting Highly Differentiated Synthetic Lethality Portfolio

Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced highlights of two posters

APRE

Read More

Mobile-health Network Solutions H1 2024 Revenue $6.6M Up From $3M YoY; Expanded Its Headcount And Expenses To Meet Increased Operational Demand And Explore New Market Opportunities, Resulting In An Increase In Net Loss Of $171,634; Cash And Cash Equiv…

Mobile-health Network Solutions (NASDAQ:MNDR) ("MaNaDr" or "the Company"), a leading Asia-Pacific telehealth provider, today announced that for the first six months of fiscal 2024 ("H1FY24") ended December 31, 2023, the

MNDR